Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

Abstract

By Week 12, nearly all patients with PP, EP and GPP achieved PASI75. The safety profile was consistent with reported results and no unexpected safety signals were observed.

IL-17 Responses Are the Dominant Inflammatory Signal Linking Inverse, Erythrodermic, and Chronic Plaque Psoriasis

“…This is consistent with recently published case series showing six out of eight erythrodermic patients achieving complete clearance with anti-IL-17 treatment (Saeki et al , 2015), but similar data on flexural psoriasis does not yet exist. In addition, our data demonstrates pronounced differences in the expression of several key pro-inflammatory cytokines between each clinical subtype, suggesting that while IL-17 may provide a common inflammatory pathway, other inflammatory signals may modify the clinical presentation and contribute to unique manifestations of each subtype.…”

IL12/IL23 Inhibition in the Treatment of Psoriatic Arthritis

“…IL17 inhibitors including secukinumab [54] and ixekizumab [55,56], and the IL17 receptor [62]. Therefore, drugs that target IL17 and its receptor are an important part of the future armament against PsA.…”

Ixekizumab for treatment of psoriasis

“…No cases of neutropenia (<1000-1500 cells/ml) were reported during the 52-week open-label extension study. In the Phase III study by Saeki et al, a decrease in mean neutrophil count was found in 18.7% of patients (-2.2 ± 1.6 billion/l), grade 1 neutropenia was found in 15 patients and grade 2 neutropenia in 4 patients [37]. Neutropenia as an adverse effect is not only observed in ixekizumab trials but also in trials with brodalumab and secukinumab.…”

“…This is a Phase III, open-label study that included [37]. Although based on a small sample size, all patients with erythrodermic psoriasis treated with ixekizumab reached PASI 75 at week 12 and maintained the effect throughout the 24-week study.…”